Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Liabilities (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Total Liabilities for 7 consecutive years, with $123.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 2.5% to $123.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123.4 million through Dec 2025, down 2.5% year-over-year, with the annual reading at $123.4 million for FY2025, 2.5% down from the prior year.
  • Total Liabilities hit $123.4 million in Q4 2025 for Allogene Therapeutics, down from $124.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $158.1 million in Q1 2023 to a low of $102.9 million in Q2 2021.
  • Historically, Total Liabilities has averaged $129.7 million across 5 years, with a median of $125.8 million in 2021.
  • Biggest five-year swings in Total Liabilities: soared 44.92% in 2022 and later fell 20.96% in 2024.
  • Year by year, Total Liabilities stood at $125.6 million in 2021, then grew by 23.14% to $154.7 million in 2022, then fell by 15.57% to $130.6 million in 2023, then dropped by 3.12% to $126.5 million in 2024, then decreased by 2.5% to $123.4 million in 2025.
  • Business Quant data shows Total Liabilities for ALLO at $123.4 million in Q4 2025, $124.4 million in Q3 2025, and $126.0 million in Q2 2025.